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ABSTRACT 
The onset of global epigenetic changes in chromatin that drive tumor proliferation 
and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic 
mechanisms that govern these changes and developing therapeutic approaches to 
modulate them, is a well-established avenue pursued in translational cancer 
medicine. Chronic myeloid leukemia (CML) arises clonally when a hematopoietic 
stem cell (HSC) acquires the capacity to produce the constitutively active tyrosine 
kinase BCR-ABL1 fusion protein which drives tumor development. Treatment with 
tyrosine kinase inhibitors (TKI) that target BCR-ABL1 has been transformative in 
CML management but it does not lead to cure in the vast majority of patients. Thus 
novel therapeutic approaches are required and these must target changes to 
biological pathways that are aberrant in CML - including those that occur when 
epigenetic mechanisms are altered. These changes may be due to alterations in 
DNA or histones, their biochemical modifications and requisite ‘writer’ proteins, or to 
dysregulation of various types of non-coding RNAs that collectively function as 
modulators of transcriptional control and DNA integrity. Here, we review the 
evidence for subverted epigenetic mechanisms in CML and how these impact on a 
diverse set of biological pathways, on disease progression, prognosis and drug 
resistance. We will also discuss recent progress towards developing epigenetic 
therapies that show promise to improve CML patient care and may lead to improved 
cure rates. 
 
INTRODUCTION 
Chronic myeloid leukemia (CML) arises when the t9;22 translocation (the 
Philadelphia chromosome) [1, 2] occurs in a hematopoietic stem cell (HSC), resulting 
in constitutive expression of the fusion tyrosine kinase BCR-ABL1 [3], and 
transformation of the HSC into a leukemic stem cell (LSC). The clonal 
myeloproliferative neoplasm that follows is driven by BCR-ABL1 expression and 
subversion of normal signalling pathways. CML is rare with an annual incidence of ≈ 
1-2 cases per 100,000 individuals and a peak incidence in the sixth to seventh 
decade of life [4]. The vast majority (85-90%) of patients present in chronic phase 
(CP) and then, if untreated, progress to advanced phase (AP) and blast phase (BP) 
within five years [5] resembling an acute leukemia with poor prognosis. The 
development of potent tyrosine kinase inhibitors (TKI), such as imatinib, which target 
BCR-ABL1 is arguably the best example of a targeted cancer therapy. TKI were 
introduced into the clinic almost two decades ago and have transformed the 
management of CML [6, 7]. However, they have not cured CML for the vast majority 
of patients as only 10-20% of them can discontinue therapy and achieve long-term 
treatment-free remission (TFR) [8-10]. More recent evidence suggests that the 
proportion achieving TFR will increase, with as many as 46% of patients on longer 
term therapy (> 8 years) or 2nd generation TKI (2G-TKI) qualifying for TKI 
discontinuation [11], with half of these likely to achieve TFR [12]. A quarter of 
patients will fail TKI therapy [13], most often due to the acquisition of BCR-ABL1 
kinase domain or other mutations [14, 15] and in a minority of cases as a result of 
progression to AP/BP [16]. For the remaining ≈ 50-60% of patients on life-long TKI, 
minimal residual disease is maintained by a sub-population of LSC[17] in the bone 
marrow (referred to as LSC persistence) [18-21] which are TKI-resistant [22-24] and 
can serve as a reservoir for disease relapse if TKI therapy is discontinued. Thus, in 
order to improve cure rates for CML, there is still a significant clinical need to 
develop novel therapeutic approaches that target LSCs and are effective for patients 
who fail TKI therapy. Many of the pathways subverted by BCR-ABL1 have been 
studied intensively as a means of identifying dysregulated components that can be 
selectively targeted to eradicate the disease when used in combination with, or as an 
alternative to, TKI (reviewed in detail in [16]).  
It is now widely acknowledged that cancers are, in part, epigenetically-driven 
diseases, where epigenetic dysregulation acts in concert with genetic abnormalities 
to provide an environment to facilitate tumor formation, maintenance and 
progression. Indeed, in a stem cell disease such as CML, the consequences of such 
dysregulation may have heightened importance as epigenetic processes are known 
to be critical for stem cell maintenance and development [25-27]. Epigenetic 
processes are typically defined within three broad categories: histones and histone 
modifications, DNA methylation, and non-coding RNAs. Collectively can exert their 
effects to (i) directly regulate transcription, DNA damage/repair and DNA replication, 
(ii) regulate RNA levels and stability post-transcriptionally, and (iii) regulate protein 
translation or post-translational protein modifications (Figure 1). Mutations in 
components of these pathways are relatively rare in CP CML (Table 1), pointing to 
epigenetic dysregulation via other ways. Such mutations are detected, however, at 
higher frequency during disease progression and the proportions of leukemic cells 
which carry mutation(s) can change in response to TKI therapy . For the purposes of 
this review we will present examples of how each of these three categories of 
epigenetic processes is dysregulated in CML, how they impact on critical pathways, 
and how they may provide new therapeutic opportunities to overcome the current 
clinical bottlenecks and improve cure rates for CML. 
HISTONE MODIFIERS AND MODIFICATIONS 
Biochemical post-translational modifications of histone tails within 
nucleosomes of chromatin [28], such as methylation or acetylation, can alter 
chromatin condensation and topology or provide sites of recruitment for other 
factors. Such modifications or marks are regulated by ‘writer’ proteins with opposing 
enzymatic activities; for example, histone acetyl- or methyl- transferases (HATs and 
HMTs) or histone deacetylase or demethylases (HDACs and HDMs) that can add or 
remove modifications, respectively, at specific amino acid residues. Further levels of 
complexity are contributed by histone variants [29] and the ability of ‘writer’ proteins 
to target the post-translational modification of non-histone proteins (Figure 1). In 
CML, a number of these histone marking systems are dysregulated, the 
consequences of which effect numerous pathways that leukemic cells utilise for 
survival (Table 2). 
DNA damage, H2AX and histone acetylation. Histone variant H2AX is 
incorporated into chromatin at varying frequencies [30] and is a known tumour 
suppressor - haplo-insufficiency of which can facilitate progression to BP in a CP-
CML murine model [31]. It is widely known that the phosphorylated form of H2AX, 
known as γ-H2AX, found at sites of DNA damage in chromatin, is a critical mediator 
in the cellular decisions that lead to DNA repair or apoptosis [32, 33]. Several lines of 
evidence point to dysregulation of this response in CML. Higher basal levels of γ-
H2AX are found in CML cells compared to normal [34, 35], consistent with the 
findings that cells expressing BCR-ABL1 show enhanced levels of oxidative DNA 
damage, including point mutations and double-stranded breaks (DSBs) induced by 
endogenous reactive oxygen species (ROS) [36, 37]. Inducing additional DSBs in 
CML and non-CML CD34+ cells results in further increases in γ-H2AX that persist 
longer in CML. Earlier reports in cell line models suggested the CML response was 
of a short duration – in keeping with a more rapid response to DNA damage [38] via 
the error-prone DNA repair mechanisms known to be active in CML cells [39-41]. 
CML cells also show increased levels of H3 and H4 acetylation which co-localizes 
with γ-H2AX at sites of DNA damage [34]. These acetylation changes are likely to 
reflect a more generalised increase in histone H3 and H4 acetylation and HAT 
activity and a reduced HDAC activity in CML - all of which are dependent on BCR-
ABL1 kinase activity [34, 42]. Altering the balance of HAT/HDAC activity in CML cells 
may also lead to increased TP53 acetylation at residues that can block the 
translocation of TP53 from the nucleus to the cytoplasm and prevent mitochondrial-
dependent apoptosis in response to DNA damage [43]. One possible mechanism for 
this imbalance in acetylation/deacetylation is the ability of BCR-ABL1 to sequester 
HDAC1 in the cytoplasm [42], which has the additional effect of promoting 
expression of BCR-ABL1 through increased nuclear H4 acetylation in a positive 
feedback loop (Figure 2a).  
SUV39H1 loss of function and lysine methylation. Histone H3 lysine 9 
trimethylation (H3K9me3) is a hallmark of heterochromatin with the 
methyltransferases SETDB1, SUV39H1 and SUV39H2 responsible for its deposition. 
However, it also plays roles in the cell-type repression of lineage-inappropriate 
genes during development [44] and is dysregulated across cancer types [45, 46]. CP 
CML CD34+ cells and granulocytes show significantly reduced levels of H3K9me3 
[47, 48] compared to normal, although appreciable levels of both H3K9me2 and 
H3K9me1 (associated with less repressive chromatin states) are evident in 
granulocytes [48]. Mechanistically, reductions of H3K9me3 levels in CP CML CD34+ 
cells are linked to cytoplasmic co-localisation of SUV39H1 by BCR-ABL1 and 
support a model whereby normal nuclear activity of SUV39H1 [47] and also HDAC1 
[42] (see section above) are subverted. This would create a more permissive 
transcriptional chromatin environment and facilitate expression of genes normally 
repressed by the SUV39H1/HDAC1 complex [49]. Later work has shown the 
opposing effects of H3K9me3 and histone H3 serine 10 phosphorylation (H3S10p) in 
CML cells. Inhibition of the kinase activities of either BCR-ABL1 or the ‘writer’ protein 
Aurora kinase B (AURK) results in loss of H3S10p and increases H3K9me3 levels, 
thus repressing BCR-ABL1 expression [50]. Collectively these results are compatible 
with the model proposed in Figure 2a. 
PRMT5 and arginine methylation in LSC survival. Histone arginine methylation, 
laid down by the PRMT family of HMTs, can activate or repress transcription 
depending on the histone residues and the dimethyl isomers (a = asymmetrical or s 
= symmetrical) involved [51]. Early work on one family member, PRMT5, showed it 
to interact strongly with the V617F mutant form of JAK2 found in BCR-ABL1-
negative myeloproliferative neoplasm [52]. Later, PRMT5 was shown to be a critical 
regulator in neuronal stem cell renewal [53] and, more recently, in CML LSC survival 
[54]. PRMT5 is upregulated by STAT5 in CML CD34+ cells where it is associated 
with increased histone arginine methylation compared to normal CD34+ cells. 
Genetic or pharmacological inhibition of PRMT5 enzymatic activity in CML CD34+ 
cells diminished this methylation and significantly reduced LSC numbers in vitro and 
reduced long-term engraftment potential in murine xenografts. The critical role for 
PRMT5 in CML is thought to be centred on the epigenetic regulation of canonical 
Wnt signalling – a pathway known to be essential for LSC function [55, 56] (Figure 
2b). In LSC, elevated PRMT5 activity triggers up-regulation of DVL3, an upstream 
positive regulator of β-catenin, as a consequence of elevated H3 arginine 2 
dimethylation (H3R2me2) at the DVL3 promoter. Intriguingly, elevated PRMT5 
activity also leads to down-regulation of the microRNA (miRNA; miR) miR-203, a 
negative regulator of BCR-ABL1, through H3 arginine 8 and H4 arginine 3 
dimethylation (H3R8me2s and H4R3me2s respectively) at the miR-203 promoter. 
Reduction of miR-203 creates a scenario where BCR-ABL1 and downstream 
PRMT5 expression are reinforced in a positive feedback loop. 
The polycomb group proteins. The polycomb group proteins found in either 
polycomb repressive complex 1 (PRC1) or complex 2 (PRC2) are arguably some of 
the best characterised ‘writer’ complexes and function as potent repressors of gene 
expression [57, 58]. Component of these complexes are de-regulated across many 
cancer types where they can act as either tumor suppressors or oncogenes [59, 60]. 
PRC2 is a multi-protein complex that contains either the HMT EZH1 or EZH2 and 
lays down histone H3 lysine 27 mono-, di- and tri-methylation. The trimethylated form 
(H3K27me3) is a hallmark of PRC2-EZH2 repressive activity. Several studies have 
demonstrated dysregulation of PRC2 in CML primary patient material, cell lines or 
murine models [61-64] and their expression levels may be altered in response to TKI 
[64, 65] or progression to BP disease [66]. Two recent studies have demonstrated 
the important role of EZH2 in LSC survival. Loss of EZH2 HMT function in either a 
murine model of CML, or in CP patient samples examined in vitro or in murine 
xenografts, significant impairs LSC survival [63, 64]. In human LSC, this was shown 
to be due to an increased dependency of pro-apoptotic genes on PRC2-EZH2 
repression which is not evident in HSC (Figure 2c). Others have shown that EZH2 
dysregulation (controlled by BCR-ABL1 via MYC and STAT5) may have other 
consequences in CML cells. EZH2 associates with β-arrestin to drive H4 lysine 
acetylation and BCR-ABL1 expression [61], or with PRAME to repress the function of 
the death receptor TNFSF10 [67]. The microRNA miR-219 is down-regulated 
through the action of EZH2 and DNA methylation at its promoter; this facilitates the 
up-regulation of XIAP, an anti-apoptotic factor and known miR-219 target. Whether 
all of these events occur in LSC is not known but provides the basis for further 
studies. 
The PRC1 complex works co-operatively with PRC2 and presence of both PRC2 
and PRC1 leads to chromatin compaction and transcriptional silencing of target 
genes [57]. PRC1 binds to H3K27me3 in chromatin, and lays down histone H2A 
lysine 119 ubiquitinylation, through the action of its catalytic components – the E3-
ligases RING1 or RING2. The stem cell factor BMI1 (also known as PCGF4) is a 
core component of PRC1 activity and emerging evidence supports it having an 
important role in cancer. In CP-CML, levels of BMI1 are elevated in total 
mononuclear and CD34+ cells compared to normal [68, 69]. Several pathways 
known to be important in CML cell survival have been shown to be the targets of 
PRC1-BMI1 activity. In one study, BMI1 was shown to repress the expression of 
ZMYM3 in CML, a component of HDAC complexes [69] (Figure 3a). ZMYM3 
repression was linked to up-regulation of the oncogene FOS via histone H3 
acetylation – thus activating a pathway recently shown to be critical for TKI-resistant 
LSC and progenitor survival [70]. BMI1 was also shown to directly down-regulate 
CCNG2 in CML cells - a regulator of the tumor suppressor PP2A, a known modulator 
of Wnt signalling [71, 72]. Up-regulating CCNG2 was able to dissociate PP2A 
subunits and drive an autophagic response in CML cells via PKCζ and ERK/JNK 
signalling [73] (Figure 3a). The role of autophagy in CML LSC is well documented 
[74-76] and BMI1 inhibition could sensitize CML cells to autophagy inhibitors.  
Epigenetic ‘writers’ and non-histone targets. Repression of apoptosis is a central 
survival mechanism and unifying theme across cancer types. Therefore it follows 
that inactivation of TP53 itself is one of the few non-histone targets of epigenetic 
’writer’ activity in CML that has thus far been identified. Inactivation of TP53 can be 
achieved through acetylation by HATs (see also above) or through deacetylation by 
HDACs such as SIRT1, a NAD-dependent deacetylase [77]. SIRT1 expression is up-
regulated in CP-CML CD34+ cells and is further elevated during disease progression 
[78, 79]. The dysregulation of SIRT1 expression in CML is likely to be epigenetically-
driven by aberrant DNA methylation (Figure 3b) and is discussed further below. 
Inhibition of SIRT1 has been shown to significantly increase TP53 acetylation, 
resulting in up-regulation of the apoptotic response and a reduction of LSC and 
progenitor cell survival in vitro and in murine models [79]. One unexpected and 
additional function of SIRT1 in CML is that it promotes the acquisition of genetic 
mutations by deacetylating components of the DNA repair machinery and increasing 
error-prone DNA repair [80]. Thus, the duality of SIRT1 function in CML allows DNA 
damage to be accumulated, whilst suppresses cell death – making SIRT1 an 
interesting player in the DNA damage response via its non-histone activities.  
DNA METHYLATION 
DNA methylation represses gene transcription and occurs at cytosine 
residues in CpG dinucleotides where it is laid down by DNA methyl transferases 
(DNMTs) and removed passively through cell division or actively by methyl-cytosine 
dioxygenases (also known as ten-eleven translocation proteins; TETs) [81]. CpG 
methylation occurs throughout genomes [82, 83], however, it is at promoter regions 
in CpG islands [84-86] that its effects on transcriptional repression are normally 
exerted. Cancer genomes have been shown to exhibit widespread global 
hypomethylation in addition to more targeted gains or loss of DNA methylation at 
tumor suppressors or oncogenes [87, 88]. Spanning more than twenty year of CML 
research, candidate gene approaches have been instrumental in identifying 
changes in DNA methylation at specific genes (Table 3). 
DNA methylation and CML survival pathways. Three examples of epigenetically-
dysregulated genes in CML, in particular, highlight the impact that dysregulating 
DNA methylation may have on CML survival pathways. Firstly, the upregulation of 
SIRT1 in CML (see also above) can most easily be explained by hypermethylation 
of the HIC1 gene – a repressor that functions in concert with SIRT1 [89] to auto-
regulate SIRT1 expression (Figure 3b). The promoter of HIC1 is hypermethylated 
in CP, and this increases during disease progression [90] and coincides with 
upregulation of SIRT1 [78]. Thus, reduction of HIC1 expression would facilitate the 
up-regulation of SIRT1 via STAT5 [78]. However, whilst this mechanism has been 
proposed [79], it has not been empirically tested. Secondly, the tumor suppressor 
MTSS1 is down-regulated in LSC and progenitor cells of CML mouse models and 
CP patients at diagnosis, but is restored to normal levels during TKI therapy [91]. 
MTSS1 down-regulation is linked to higher DNA methylation levels at its promoter 
in CML compared to normal and is accompanied by the recruitment of the 
transcription factor ZBTB33 (KAISO) and the potent repressor REST1 [92, 93] 
(Figure 3c). MTSS1 is a known target of DNMT3B [94], and both methylation and 
DNMT3B levels have an inverse relationship with MTSS1 expression in naïve and 
TKI-treated cells. Repression of MTSS1 is likely to promote CML LSC and 
progenitor cell proliferation and motility, both of which can be reduced upon MTSS1 
enforced expression [91]. Treatment with the de-methylating agent 5-azacytidine in 
vitro was able to strongly induce MTSS1 in CML cell lines. Finally, the CD70/CD27 
axis has been shown to activate non-canonical Wnt signalling in the presence of 
TKI, thus contributing to LSC survival [95]. This is due to the opposing effects that 
TKI has on expression of DNMT1A and SP1 via the suppression microRNA miR-29 
(Figure 3d). Lowering miR-29 expression allows SP1 levels to increase, whilst 
reducing DNMT1A. This results in loss of DNA methylation at the CD70 promoter 
and CD70 activation by SP1 which can then drive Wnt signalling and β-catenin 
stabilization. CD70 knockdown synergized with TKI treatment to eliminate LSC in 
both xenograft and retroviral mouse models [95].  
 
NON-CODING RNAs 
Non-coding RNAs are a more recently emerging epigenetic process that can 
regulate mRNA levels and protein translation through a variety of somewhat related 
processes (Figure 1). Anti-sense transcripts are long non-coding RNAs (lncRNAs) 
that are transcribed from the strand opposite to that of the sense transcript; for this 
reason, they can result in transcriptional interference with the sense transcript by a 
variety of mechanisms [96, 97]. miRNAs are small or short non-coding RNA of ≈ 20-
23 nucleotides, that are processed from longer precursor RNAs. They regulate gene 
expression through sequence-specific binding most often to the 3’ untranslated 
regions of target mRNAs and either prevent translation or induce cleavage of the 
mRNA [98]. miRNAs may also compete for target mRNAs, according to the 
competitive endogenous RNA (ceRNA) hypothesis [99-101]. Of these various 
processes, the roles of miRNAs, in particular, are well established in cancer biology 
[102, 103]. While there are relatively few reports of lncRNAs or ceRNAs being 
dysregulated in CML cells compared to normal, the number of dysregulated miRNAs 
is considerable (Table 4). 
MicroRNAs, the niche and the CXCL12/CXCR4 axis. The impact of dysregulated 
miRNAs on a number of cellular pathways in CML is shown in several of the 
examples above (Figures 2b, c, 3d) and is also reviewed in detail elsewhere [104-
111]. One other area of miRNA biology that is germane to the discussions here is 
how they regulate non-cell autonomous pathways via exosomal transfer between cell 
types [112-114]. In CML, the expression of the chemokine CXCL12 in the bone 
marrow microenvironment (BMM) and its receptor CXCR4 expressed on LSC have 
been demonstrated to play roles in LSC homing and survival [115-118]. In CML, 
interactions between leukemic cells and the bone marrow stroma are defective due 
to BCR-ABL1 suppression of CXCR4-mediated signalling (Figure 3e). This, in turn, 
reduces homing capacity and allows primitive CML cells to escape from the bone 
marrow [119]. Extrapolation of recent evidence obtained from CML cell lines in co-
culture with endothelial cells [120] suggests that exosomal transfer of miR-126 from 
leukemic cells to stromal cells may also inhibit CXCL12/CXCR4 signalling in vivo 
through down-regulation of CXCL12 in the stroma. Levels of miR-126 in exosomal 
vesicles of CML cell lines are higher than in the parent cells producing them. 
Tracking experiments demonstrated that miR-126 can be transferred from leukemic 
to endothelial cells, where it can target the down-regulation of both CXCL12 and 
VCAM1, the consequences of which are reduced cell motility and adhesion between 
the two cell types. This would support the view that exosomal ‘shuttles’ may have an 
important role in CML-stromal cell interactions in the BMM.  
EPIGENETICS IN PROGRESSION AND PROGNOSIS 
In addition to epigenetic processes having roles in subverting critical cellular 
pathways in CML, they are also further dysregulated during disease progression.  
Histone modifiers. Granulocytic H3K9me3 levels increase during AP and BP in 
concert with increased levels of the H3K9me3 binding protein, HP1, suggesting that 
both features may serve as biomarkers of disease progression [48]. BMI1 increases 
further during progression from CP to BP [65, 66]. Furthermore, BMI1 was shown to 
be approximately two-fold elevated in AP- and BP-CML as compared to CP, both in 
PBMCs and PB CD34+ cells [121]. In a retrospective cohort of 64 patients with CP 
CML, above-median levels of BMI1 mRNA expression in CD34+ cells at diagnosis 
were associated with significantly inferior survival as compared to below-median 
BMI1 levels [121]. Thus, high BMI1 expression was predictive of poor outcome in 
patients with CML.  
Later work provided a possible explanation for the role of BMI1 in disease 
progression. Using the tetracycline-controlled SCLtTA/BCR/ABL mouse model 
reflecting CP CML [122], one study showed that BMI1 was able to reprogram B-
lineage progenitor cells during CP CML-like disease and to turn them into B-cell 
acute lymphoblastic leukemia (B-ALL) initiating cells [123]. The B-ALL was serially 
transplantable. Overexpression of BMI1 in hematopoietic stem cells (HSCs) or 
multipotent progenitors (MPPs) did not result in B-ALL in vivo, as assessed by 
limiting dilution analysis [123]. The presence of continuous BCR-ABL1 was required 
for the ALL phenotype, since abrogation of BCR-ABL1 expression by doxycycline re-
administration rescued the mice from ALL-mediated lethality [123]. Thus, these data 
suggest that in patients with CML, BMI1 may synergize with BCR-ABL1 to induce 
lymphoid blast crisis by transforming B-lineage progenitors expressing BCR-ABL1. 
Immunophenotypic data on the type of blast crisis were not provided in the 
retrospective expression cohort [121] but a second functional study showed that 
BMI1 overexpression in human CD34+ cells from CML patients induced 
transplantable B-lineage ALL after transplantation of these cells into NOD/SCID mice 
[124]. This study also showed that BMI1 induced BCR-ABL1 positive acute leukemia 
was biased towards the lymphoid lineage, supporting the above-mentioned mouse 
model [123, 124]. The mechanism may involve p16 and p19 (equivalent to human 
p14) repression and possibly EBF1, PAX5, and IKZF1 downregulation [123, 124]. 
DNA methylation. Reports of hypermethylation during disease progression at 
genes such as CDKN2A [125-129], CDKN2B [126-133], CALCA [134-136], and 
DAPK1 [126, 127, 137, 138] among others are all reviewed in detail elsewhere 
[106, 109]. Aside from these, one of the most cited epigenetic hallmarks in CML is 
increased levels of DNA methylation at the Pa promoter of ABL1 in mononuclear 
cells from blood or bone marrow [130, 133, 139-145]. The Pa promoter is the 
second most 5’ promoter of the ABL1 gene and is normally retained within the 
chimeric BCR-ABL1 gene of the Ph chromosome in CML. Pa hypermethylation in 
CP is highly variable, though significantly different compared to normal where it is 
generally unmethylated. The percentage of CP patients showing increased Pa 
methylation ranged from as low as 26% [140] up to between 77-81% [130, 133, 
142], although such variations may be attributable to the different technologies 
used in different studies. Both the percentage of patients with Pa methylation and 
the levels of methylation has been shown to increase during disease progression 
across several studies [133, 139, 141, 142]. However, the degree of Pa methylation 
does not correspond to the level of full length BCR-ABL1 transcripts [144] in BP. 
Taken together, these data add further fuel to the discussion about the prognostic 
value of Pa promoter methylation in CML progression [146]. 
Recently, the true scope of changes in DNA methylation across CML methylomes 
during disease progression has been demonstrated. Reduced representation 
bisulfite sequencing (RRBS) was used to survey methylation at 2.6 million CpG 
dinucleotides and detected differences between controls and CML samples in all 
three phases of disease [147]. Only ≈ 600 CpG were found to be differentially 
methylated in CP disease compared to healthy controls. However, this number 
increased by ten-fold to ≈ 6,500 in BP where 897 genes were dysregulated, with 
the majority showed increases in DNA methylation and reduced mRNA expression. 
Most of the 897 genes had not previously been identified as being differentially 
methylated in CML in two earlier microarray-based approaches which employed 
targeted bisulfite sequencing [133, 148].  
MicroRNAs. The miR-17/92 cluster which encodes for six miRNAs processed from a 
single transcript is over-expressed in CML cell lines and CD34+ cells from CP and 
BP [149-151]. However, there are conflicting views as to whether it is over-
expressed in CP [152], with one study showing that expression of this cluster is only 
slightly elevated or at normal levels in PB MNC at diagnosis [152]. However, these 
conflicting data can be reconciled by hypothesizing that different miRNAs of the 
cluster may be dysregulated during different phases of disease and in different cell 
types (CD34+ versus total PB MNCs). 
EPIGENETICS IN THERAPEUTIC RESPONSE AND RESISTANCE  
Drug resistance. Genetic aberrations such as point mutations in the BCR-ABL1 
fusion gene [153-155] or additional chromosomal translocations [156, 157] have 
strongly been implicated in primary and/or secondary resistance to TKI treatment in 
CML. However, epigenetic dysregulation is also increasingly found to play a causal 
role in TKI resistance and we have already pointed to several examples (EZH2, 
PRMT5, SIRT1, MTSS1, CD70) where combining TKI with novel drugs is able to 
overcome such resistance in LSC or progenitor cells in pre-clinical models [54, 63, 
64, 79, 91, 95]. However, there are other examples supported by analysis of CML 
cohorts during TKI therapy. 
High expression of PRC1 members is associated with decreased imatinib sensitivity. 
In 30 patients with CML, pre- and post-imatinib bone marrow-derived samples were 
analyzed for the expression of PRC1 components [158]. During imatinib treatment, 
the mRNA expression of BMI1, PHC3, CBX6, and CBX7 was significantly increased, 
and post-treatment levels of CBX6, CBX7 were predictive of the 3-month response 
rate to imatinib. In addition, BMI1 expression post-treatment level measurements 
improved the predictive power of hOCT-1 genotyping as a predictor of imatinib 
response [158]. 
Increased DNA methylation was linked to down-regulation of BCL2-interacting 
mediator (BIM) in 36% of a cohort of 100 CML patients and was associated with a 
decrease of optimal imatinib responses [159]. BIM re-expression by 5-azacytidine 
treatment was shown to be required for imatinib-induced apoptosis of CML cell lines 
BV173 and KU81212. In another study, HOXA4 promoter methylation was detected 
in cells from 95 CML patients and was positively correlated with imatinib resistance 
[160], but, here, no data on HOXA4 expression or function were provided. Two 
studies showed that DNA hypermethylation were also associated with resistance to 
adriamycin and interferon/cytarabine/hydroxyurea. In the first, down-regulation of 
mitochondrial ATPase β-subunit ATP5B expression decreased the sensitivity of 
K562 cells to adriamycin [161]. Likewise, silencing of p16INK4A and p14ARF 
expression by was associated with poor response to interferon and cytarabine +/- 
hydroxyurea therapy, and it correlated with CML progression [125].  
In a more comprehensive study, K562 cells or cells from 120 CML patients were 
subjected to analysis of DNA methylation of CpG islands in the promoters of ten 
genes (ABL1, CDH13, CDKN2B, DPYS, NPM2, OSCP1, PDLIM4, PGR-A, PGR-B, 
TFAP2E) which had previously been linked to myeloid malignancies [133]. Patients 
were imatinib-responsive (n=30), imatinib-resistant (n=50), imatinib-intolerant (n=10), 
or imatinib-naïve (n=30 from the pre-imatinib era). Sample were taken during CP 
(n=65), AP (n=40), or BP (n=15). K562 cells showed extensive hypermethylation 
(15% of total CpG sites) and, although less extensive, also hypomethylation. There 
was an overall inverse correlation of gene expression with promoter methylation. Of 
the ten genes analyzed by bisulfite sequencing, five genes showed significantly 
increasing fraction of CpG-methylated cases with increasing disease severity (with 
an average of 4.5, 6.2, and 6.8 methylated genes in CP, AP, and BP, respectively). 
More interestingly, there was a highly significant increase in the number of 
methylated genes in cells from imatinib-resistant or -intolerant vs. –responsive 
patients [133]. Finally, promoter methylation of the PDLIM4 gene was significantly 
inversely correlated with survival of the patients [133]. 
Dramatic down-regulation of miR-150 compared to normal is a hallmark of CP CML 
CD34+, mononuclear cells and total leukocytes at diagnosis [150, 152, 162-165], and 
rapid reversal of this during imatinib therapy [163] is consistent with imatinib-
responders [152]. Indeed, the degree of down-regulation of several miRNAs can 
distinguish imatinib responders from non-responders in drug-naïve CP diagnostic 
samples. These include miR-29 cluster [166, 167], miR-23a [165, 166] and miR-451 
[150, 152, 168, 169]. Furthermore, BCR-ABL1 is a validated target of miR-451 [170], 
and this may explain the inverse relationship between the expression of BCR-ABL1 
and miR-451 that is observed in some patients during response to imatinib [169]. 
However, further mechanistic studies are required to understand why differing 
miRNA levels in diagnostic samples are able to define differing clinical outcomes. 
Epigenomic variability may also play a major role in resistance to TKI treatment. In a 
functional assay using single-cell RNA-seq and GATA-mediated single-cell ATAC-
seq in K562 cells, GATA accessibility was found to show large variations [171], and 
this was associated with high variability of CD24, CD44, and CD62 expression. 
Interestingly, functional analysis revealed that the CD24hi-expressing but not the 
CD24lo-expressing subpopulation showed increased resistance to imatinib-induced 
apoptosis and suppression of colony forming units [171]. These in vitro data suggest 
a model by which not only genetic but also epigenetic variation among subclones 
may provide the fertile grounds for therapy resistance, clonal evolution, and, 
ultimately, progression of CML during TKI therapy. 
Epigenetic drugs in clinical trials. Given the impact of epigenetic dysregulation in 
CML, clinical trials have been conducted to assess the efficacy and tolerability of 
epigenetic drugs in CML. In a study of 50 patients with myeloid malignancies who 
were treated with decitabine, five patients with CML were included (1 CP, 1 AP, 3 
BP). Of these five patients, two achieved a CR and two patients attained a PR. 
However, response duration was short with 1 to 9 weeks, there was no correlation 
with CDKN2B promoter methylation, and no data on cytogenetic or molecular 
responses were reported [172]. In a subsequent study, 35 imatinib-resistant CML 
patients (12 CP, 17 AP, 6 BP) were treated with decitabine [173]. Toxicity was 
reported as mild. In CP, 50% of patients achieved a CHR, and the overall response 
rate was 83%, with 25% major cytogenetic responses. Again, these responses were 
generally short-lived, but occasional long-term responses occurred, leading to an 
overall significant superiority of survival in the decitabine responders vs. non-
responders [173]. Hypomethylation of LINE elements was observed, but this was not 
durable [173]. Significantly better overall survival was also reported in a subsequent 
study of a combination of decitabine and imatinib in 28 CML patients (18 AP, 10 BP), 
most of whom were already imatinib-resistant [174]. In this cohort, 50% of AP and 
30% of BP patients showed overall responses, with 39% and 20% of each group 
respectively achieving cytogenetic remission. Again, overall survival was significantly 
better in the responders, with a plateau during the first 50 weeks, but subsequently 
declined [174]. In a small case series of eight patients with imatinib-resistant CML (1 
CP, 5 AP, 2 BP), addition of two HDAC inhibitors, hydralazine and magnesium 
valproate, to imatinib therapy resulted in clinical responses during a median of 18 
months of follow-up. Adverse events included mild neurological symptoms but no 
grade 3 or 4 toxicities [175]. Thus, addition of HDAC inhibitors may be beneficial in 
TKI-refractory CML patients when no other options exist. 
Together, the data from these clinical trials show that treatment with epigenetic drugs 
can induce objective responses in patients with CML, even in advanced stages and 
despite imatinib-refractoriness. However, these responses are usually not durable, 
and other treatment strategies have to be pursued. Currently, not only do several TKI 
options exist (i.e. imatinib, dasatinib, nilotinib, bosutinib, and ponatinib), but novel 
agents are being tested (i.e. ABL001 [176]), and allogeneic transplantation remains 
as a potentially curative option for patients with advanced or non-responsive 
disease. The reason for the short-lived responses may well be our limited 
understanding of the magnitude and complexity of epigenetic aberrations and the 
difficulty to revert these changes by a single drug. 
 
FUTURE PROSPECTS 
The advent of the genomics era has greatly influenced the understanding, diagnosis, 
and treatment of cancer. Probably among the most affected are patients with chronic 
myeloid leukemia (CML). Soon after the realization of the dramatic success of 
targeted therapies against the BCR-ABL1 oncogene, molecular therapies have been 
spreading to other cancers, making CML one of the most important and best-
understood paradigmatic malignancies in the field of oncology. Not only has high-
sensitivity PCR monitoring of BCR-ABL1 transcripts long entered clinical practice, 
leading to important treatment decisions, but the concept of oncogene addiction of 
LSC, treatment-emergent oncogenic resistance due to BCR-ABL1 mutations, and, 
lately, the concept of TFR and operational cures have all been developed bench-to-
bedside-and-back in the context of CML. 
While genetic factors are clearly important, epigenetic modifications are now 
increasingly being recognized as crucial mechanisms of CML pathogenesis, 
progression, and treatment resistance. With the currently evolving technologies of 
whole-genome sequencing, single-cell RNA-seq, histone modification mapping, and 
genome-wide DNA methylation, etc, we are experiencing a time where a much more 
comprehensive description of CML biology comes within grasp. It can be expected 
that soon the diagnosis of patients with CML will be much more exact than currently, 
including sub-clonal analysis and ultra-deep monitoring. Yet, many questions still 
remain unanswered and unsolved, such as the question of optimal treatment of 
patients with accelerated and blast phase, the prerequisites for successful treatment 
discontinuation, and the factors for long-term remission. Recently, CML CD34+ cells, 
highly enriched for LSC, were demonstrated to be killed by p53 stabilization 
combined with BET inhibitor-mediated chromatin disruption [177]. Furthermore, BET 
inhibitors can decrease PD-L1 expression on solid tumor cells [178, 179], and it is 
tempting to speculate that this downregulation may facilitate activation of immune 
checkpoints and long-term clearance of LSC, similar to suppression of PD1 on T 
cells in CML patients with TKI-induced deep molecular remission [180]. The short-
lived duration of responses to epigenetic drugs in the clinic is also an area that is 
poorly understood. However, recent studies suggests that BET inhibitor resistance is 
likely to be driven by pre-existing clones which display a high degree of 
transcriptional plasticity, making them highly adaptive with the possibility of reversion 
to BET sensitivity when treatment is discontinued [181, 182]. Such resistant clones 
also have altered epigenetic landscapes – pointing to epigenetic-based resistance 
mechanisms that will require further investigation. These findings may also have 
broader implications for all types of epigenetic drugs as stand-alone therapies.  
Thus, epigenetic factors clearly will continue to play a role in CML treatment and 
prognosis, and the elucidation of critical pathways in cancer initiation, maintenance, 
and successful elimination of LSC will continue to benefit from CML research. 
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FIGURE AND TABLE LEGENDS 
Figure 1. Layers of epigenetic regulation in CML. Expression of BCR-ABL1 
subverts a number of signalling pathways (examples shown) which contribute to, or 
result from, epigenetic dysregulation in CML cells. The schematic diagram illustrates 
the three classes of epigenetic processes that have been widely studied and 
regulate transcription and DNA damage/repair in CML (DNA methylation, histone 
modifications and non-coding RNAs). Nucleosomes are composed of 2 molecules of 
histones H2B, H2A, H3 and H4 and are shown here for simplicity as spheres around 
which the DNA double helix is entwined. Protein-coding or non-coding genes are 
shown as the coloured rectangles between nucleosomes. DNA methylation is shown 
at CpG sequences and the process of demethylation is represented by the addition 
of –OH. HATs = histone acetyltransferases. HDACs = histone deacetylases. HMTs = 
histone methyltransferases. HDMs = histone demethylases. DNMTs = DNA 
methyltransferases. TETs = Ten-eleven translocation enzymes. lncRNA = long non-
coding RNA. ROS = reactive oxygen species which contributes to DNA damage. All 
other symbols are described in the legend at the bottom of the schematic.  
 
Figure 2. Dysregulation of histone methylation in CML. A. Lower levels of 
histone H3 lysine 9 trimethylation are found in CML cells and this is linked to the 
direct interaction of BCR-ABL1 with SUV39H1 (and also HDAC1) in the cytoplasm. 
This creates transcriptionally permissive chromatin associated with H3 serine 10 
phosphorylation (H3S10p) and H4 acetylation at target genes, including BCR-ABL1, 
in the nucleus – thus allowing their expression [47, 48, 50]. B. A positive feedback 
loop between BCR-ABL1 and the methyltransferase PRMT5 results in increased 
levels of histone H3 arginine 2 symmetric demethylation which in turn activates Wnt 
signalling and its transcriptional targets [54]. C. In CML, re-programming of 
Polycomb Repressive Complex 2 and its methyltransferase subunit EZH2 alters the 
balance between pro- and anti-apoptotic responses via altered dependencies on 
histone H3 lysine 27 trimethylation [61-64, 67]. This may also involve a positive 
feedback loop involving BCR-ABL1 which reinforces EZH2 expression via MYC 
(public ENCODE datasets) and STAT [62]. Gene transcription is denoted by the blue 
text in italics. Steps in pathways/processes that are active in CML cells are shown 
with solid lines; steps that are blocked in CML are shown with dotted lines. All other 
symbols are as described in Figure 1. MK-0457 = Aurora kinase inhibitor; IM = 
imatinib. s = symmetrical histone arginine methylation. 
 
  
Figure 3. The diversity of epigenetic mechanisms utilised in CML cells. A. BMI1 
regulation inhibits the response to autophagy via repression of CCNG2 [73] and 
permits expression of FOS [69] - a critical survival factor [70]. B. Up-regulation of 
SIRT1 through its inability to auto-regulate lead to deacetylation and inactivation of 
TP53 [78, 79, 90]. C. The tumor suppressor MTSS1, which controls cell migration 
and proliferation, is down-regulated as a result of increased DNA methylation and 
recruitment of repressive transcription factors to its promoter [91]. D. TKI up-
regulates the Wnt/β-catenin pathway by inhibiting miR-29 expression thus allowing 
increased CD70 expression and CD70/CD27 receptor/ligand interaction [95]. E. Cell 
non-autonomous regulation of the CXCL12/CXCR4 axis may involve the exosomal 
export of miR-126 to endothelial cells in the microenvironment where it reduces 
expression of CXCL12, thus inhibiting signalling via CXCR4 in CML cells[120]. Steps 
in pathways/processes that are active in CML cells are shown with solid lines; steps 
that are blocked in CML are shown with dotted lines. All other symbols are as 
described in Figure 1.  
 
 
Table 1 
Table 1. DNA mutations/SNPs in epigenetic regulators or miRNA targets. Column one: Gene name. Column two: encoded 
protein and function (if known). Column three: epigenetic class. Column four: the type (in italics) and frequency of DNA changes are 
shown as actual number of cases (i) in CP/AP/BP CML or (ii) in TKI-responder, resistant or progressed patients [183]. Column five: 
clinical significance as described in the cited reference(s). Column six: cited reference(s). Abbreviations: CP = chronic phase; AP = 
advanced phase; BP = blast phase. 
 
GENE PROTEIN/FUNCTION EPIGENETIC CLASS TYPE/FREQUENCY* 
CLINICAL 
SIGNIFICANCE 
REFERENCE 
DNMT3A 
DNA 
methyltransferase 
DNA methylation 
mutation 
3 of 29 CP 
2 of 74 TKI responders 
pre-leukaemic lesion; 
CP-CML; TKI treatment 
[183, 184] 
IDH1 
isocitrate 
dehydrogenase 
mutation 
4 of 194 BP 
BP-CML [15, 185-188] 
IDH2 
isocitrate 
dehydrogenase 
mutation 
5 of 194 BP 
BP-CML [15, 185-188] 
TET2 
methylcytosine 
dioxygenase 2 
mutation 
3 of 138 CP 
2 of 14 AP 
9 of 79 BP 
2 of 74 TKI responders 
3 of 18 TKI resistant 
1 of 8 progressed 
CP-CML; AP-CML; BP-
CML; TKI treatment 
[15, 183-187, 189, 
190] 
TET3 
methylcytosine 
dioxygenase 3 
mutation 
1 of 24 CP 
CP-CML [189, 190] 
            
MSH6 
G/T Mismatch-Binding 
Protein  
DNA repair/replication 
mutation 
1 of 24 CP 
CP-CML [189, 190] 
            
ASXL1 
Polycomb Repressive 
Complex 2; 
H3K27methylation 
histone modification 
mutation 
12 of 139 CP 
12 of 80 BP 
3 of 74 TKI responders 
3 of 18 TKI resistant 
2 of 8 progressed 
CP-CML; BP-CML; TKI 
treatment 
[15, 183-187, 189-
191] 
EZH2 
Polycomb Repressive 
Complex 2; histone 
methyltransferase; 
H3K27methylation 
mutation 
1 of 29 CP 
CP-CML [15, 184] 
KDM1A 
HMT activity; H3K4 
and H3K9 methylation 
mutation 
1 of 24 CP 
CP-CML [189, 190] 
KMT2A 
MLL1; HMT activity; 
H3K4methylation 
mutation 
1 of 74 TKI responders 
CP-CML; TKI treatment [183] 
KMT2D 
MLL2; HMT activity; 
H3K4 methylation 
mutation 
1 of 74 TKI responders 
2 of 18 TKI resistant 
CP-CML; TKI treatment [183] 
            
ARHGAP26 
RhoGTPase; target of 
miR-18a-3p 
miRNA 
SNP 3' UTR 
rs187729 T > C 
30 of 140 CP 
increased risk of CP-
CML 
[192] 
IRF8 
interferon regulatory 
factor 8; target of 
miR-330-3p 
SNP 3' UTR 
rs10514611 C>T 
84 of 140 CP 
increased risk of CP-
CML 
[192] 
 
 
Table 2 
Table 2. Proteins implicated in histone dysregulation in CML. Column one: gene/protein name. Column two: complex in which 
the protein is normally found and its function (if known). Column three: CML cell type studied (primary patient material or cell lines; 
human unless stated). Column four: clinical significance as described in the cited reference(s). Column five: cited reference(s). 
Abbreviations: PB = peripheral blood; BM = bone marrow; MNC = mononuclear cells; LSC = leukemic stem cell; CP = chronic 
phase; BP = blast phase; ND = not determined. 
 
PROTEIN/PROTEIN 
FAMILY COMPLEX/FUNCTION CML CELL TYPE CLINICAL SIGNIFICANCE REFERENCE 
AURKB 
serine/threonine kinase; 
H3S10 phosphorylation 
K562; Ba/F3-BCR-
ABL1 (murine); 
mode of action of aurora 
kinase (AK) inhibitors; TKI 
resistance 
[50] 
BMI1 
Polycomb Repressive 
Complex 1; H2AK119 
ubiquitinylation 
PB MNC; BM MNC; 
BM CD34+; K562; 
JURL-MK1; LAMA-84 
CP-CML; disease 
progression; imatinib 
response 
[68, 69, 73, 158, 193]  
CBX6 
Polycomb Repressive 
Complex 1; H2AK119 
ubiquitinylation 
BM MNC imatinib response [158] 
CBX7 
Polycomb Repressive 
Complex 1; H2AK119 
ubiquitinylation 
BM MNC imatinib response [158] 
EED 
Polycomb Repressive 
Complex 2; 
H3K27methylation 
K562; K562-IMA3 imatinib resistance [65] 
EZH1 
Polycomb Repressive 
Complex 2; HMT activity; 
H3K27methylation 
PB CD34+CD38+/- CP-CML LSC [64] 
EZH2 
Polycomb Repressive 
Complex 2; HMT activity; 
H3K27methylation 
K562; PB 
CD34+CD38+/-; K562-
IMA3 
 down-regulation (PL3); 
inhibition (EZH2i); CP-CML 
LSC;  imatinib resistance; 
disease progression via β-
arrestin 1 
[61-65, 67, 194]  
H2AX 
recruitment to sites of DNA 
damage as γ-H2AX; 
apoptosis 
K562 
imatinib response; 
zerumbone response; 
resveratrol response; 
disease progression 
[31, 35, 195-198]  
HATs 
H3 and H4 acetylation; DNA 
damage; TP53K317/K320ac 
BCR-ABL1−32Dcl3 
(murine) 
ND [34, 43] 
HDAC1 HAT activity; H4ac PB CD34+ CP-CML; BP-CML [42] 
HDACs H3 and H4 deacetylation  
BCR-ABL1−32Dcl3 
(murine) 
ND [34] 
HP1 H3K9 methylation 
PB CD34+; PB MNC; 
PB granulocytes 
 disease progression [48] 
JARID2 
Polycomb Repressive 
Complex 2; 
H3K27methylation 
PB CD34+CD38+/- CP-CML/LSC [64] 
PHC3 
Polycomb Repressive 
Complex 1; H2AK119 
ubiquitinylation 
BM MNC imatinib response [158] 
PHF19 
Polycomb Repressive 
Complex 2; 
H3K27methylation 
PB CD34+CD38+/- CP-CML/LSC [64] 
PRMT5 
HMT activity; histone and 
protein arginine methylation 
PB CD34+; BM CD34+ all phases of CML [54] 
RBBP7 
Polycomb Repressive 
Complex 2; 
H3K27methylation 
PB CD34+CD38+/- CP-CML/LSC [64] 
SIRT1 
HDAC; histone/protein lysine 
deacetylation (TP53K382) 
PB CD34+CD38+/-; 
K562; K562-IMA3 
CP-CML/LSC; imatinib 
resistance 
[65, 78-80] 
SUV39H1 H3K9 methylation 
 32D clone 8B 
(murine); PB CD34+ 
CP-CML; response to 
imatinib 
[47] 
SUZ12 
Polycomb Repressive 
Complex 2; 
H3K27methylation 
K562; PB 
CD34+CD38+/; K562-
IMA3 
 down-regulation by PL3; 
CP-CML/LSC; BP-CML; 
imatinib resistance 
[64-66, 194] 
 
 
 
 
 
 
 
 
 
 
Table 3 
Table 3. Genes and other features with altered DNA methylation in CML. Column one: gene/feature. Column two: encoded 
protein and function (if known). Column three: status with respect to hyper or hypomethylation in CML. Column four: CML cell type 
studied (primary patient material or cell lines). Column five: clinical significance as described in the cited reference(s). Column six: 
cited reference(s). Abbreviations: PB = peripheral blood; BM = bone marrow; MNC = mononuclear cells; LSC = leukemic stem cell; 
CP = chronic phase; AP = advanced phase; BP = blast phase; IFN = interferon; WBC = white blood count; CCR = complete 
cytogenetic remission; ND = not determined.  
 
GENE/REGION PROTEIN FUNCTION STATUS IN CML 
CML CELL 
TYPE 
CLINICAL 
SIGNIFICANCE 
REFERENCE 
 up to 897 genes various hyper/hypomethylation 
PB MNC; BM 
MNC disease progression [147] 
            
ABCB1 P-glycoprotein eflux pump 
hypermethylation 
BM MNC 
imatinib resistance; 
imatinib response 
[199] 
ABL1 (Ph+ 
chrom) 
oncogene; tyrosine 
kinase 
PB MNC; BM 
MNC 
all CML stages; 
disease progression; 
independent of BCR-
ABL1 mRNA levels; 
response to IFNα 
therapy; p210 form of 
BCR-ABL1 
[130, 133, 139-146]  
ATG16L2 
autophagy-related protein 
16-2 
PB MNC; BM 
MNC 
CP-CML; BP-CML; 
disease progression  
[148] 
ATP5B  mitochondrial ATPase K562; BM MNC 
disease progression; 
adriamycin resistance 
[161] 
BCL2L11 
Bcl-2 interacting protein 
Bim 
BM MNC imatinib resistance [159, 200] 
BCR breakpoint cluster region PB MNC 
survival; imatinib 
response; imatinib 
dose; age 
[201] 
CADM1 cell adhesion molecule 1 
PB MNC; BM 
MNC 
BP-CML [132] 
CALCA 
calcitonin; G-coupled 
receptor 
PB MNC; BM 
MNC 
disease progression [134-136] 
CBY1 beta-catenin antagonist K562; BM MNC CP-CML [202] 
CD70 
tumor necrosis factor 
ligand 
KBM5r 
CP-CML; TKI 
persistent LSC 
[95] 
CDH13 caherin family member 
PB MNC; BM 
MNC 
all CML stages [132, 133] 
CDKN2A 
cell cycle inhibitor p16 
PB MNC; BM 
MNC 
AP-CML; BP-CML; 
disease progression 
[125-127] 
cell cycle inhibitor p14 PB MNC 
AP-CML; BP-CML; 
disease progression 
[125, 128, 129] 
CDKN2B cell cycle inhibitor p15 
PB MNC; BM 
MNC 
CP-CML; BP-CML; 
disease progression 
[126-133] 
CEBPA 
myeloid transcription 
factor 
PB MNC disease progression [203] 
CTSL 
lysosomal cysteine 
proteinase 
PB MNC disease progression [204] 
DAPK1 death receptor 1 
PB MNC; BM 
MNC 
sex; disease 
progression; BP-
CML; imatinib 
resistance 
[126, 127, 137, 138] 
DDIT3 DNA damage response BM MNC reduced WBC [205] 
DLX4 homeobox protein BM MNC disease progression [206] 
DPYS pyrimidine metabolism K562; PB MNC 
hypermethylator 
phenotype 
[133] 
EBF2 
early B-cell factor 2; 
transcription factor 
PB MNC; BM 
MNC 
CP-CML; BP-CML; 
disease progression  
[148] 
ESR1 estrogen receptor 1 
PB MNC; BM 
MNC 
BP-CML [132] 
FHIT cell cycle regulator BM MNC BP-CML [126] 
HOXA4 homeobox protein PB MNC imatinib resistance [160] 
HIC1 transcriptional repressor 
PB MNC; BM 
MNC 
disease progression [90] 
IGF2 insulin growth factor 2 
PB MNC; BM 
MNC 
loss of imprinting 
during diseas 
progression 
[207] 
JUNB 
transcription factor; 
oncogene 
PB MNC CP-CML; BP-CML [208] 
M-BCR 
major breakpoint cluster 
region  
PB MNC; BM 
MNC 
Ph- and Ph+ CP-CML; 
IFN remission; 
distinguish lymphoid 
and myeloid BP 
[209-211] 
MGMT DNA repair 
PB MNC; BM 
MNC 
CP-CML; BP-CML [126, 132] 
MSH1 mismatch repair ATPase  
PB MNC; BM 
MNC 
CP-CML [132] 
MTSS1 actin dynamics K562; PB MNC CP-CML [91] 
NPM2 histone chaperone K562; PB MNC 
all CML stages;               
imatinib 
intolerance/resistance 
[133] 
OSCP1 
tumor suppressor;             
pro apoptotic 
K562; PB MNC 
disease progression; 
survival (pre-
imatinib);             
imatinib 
intolerance/resistance 
[133] 
PACRG 
chaperonin-binding 
protein 
BV173; TCC-S; 
KU812; KYO-1; 
K562; BM MNC 
BP-CML (lymphoid) [212] 
PARK2 e3 ubiquitin ligase 
BV173; TCC-S; 
KU812; KYO-1; 
K562; BM MNC 
BP-CML (lymphoid) [212] 
PDLIM4 
PDZ and LIM domain 4 
protein 
K562; PB MNC 
survival (pre- and 
post-imatinib) 
[133] 
PER2 circadian clock gene PB MNC CP-CML; BP-CML [213] 
PER3 circadian clock gene PB MNC disease progression [213] 
PGRA progesterone receptor PB MNC disease progression [133] 
PGRB progesterone receptor PB MNC disease progression [133] 
PLCD1 phospholipase C BM MNC all CML stages [214] 
PRAME 
repressor of retinoic acid 
receptor 
BM MNC 
disease progression 
(hypomethylation) 
[215] 
PTPN6 tyrosine phosphatase  
PB MNC; BM 
MNC 
disease progression [216] 
RARB retinoic acid receptor β BM MNC BP-CML [126] 
RASSF1A 
cell cycle;                           
Ras signalling 
K562 ND [217] 
sFRPs 
secreted frizzled related 
proteins; Wnt signalling 
BM MNC imatinib resistance [218] 
SOCS1 
repressor of cytokine 
signalling 
PB MNC; BM 
MNC 
disease progression; 
molecular remission 
[219] 
SOCS3 
suppressor of cytokine 
signalling 
K562 imatinib resistance [220] 
SPI1 transcription factor PU.1 
K562; PB MNC; 
BM MNC 
disease progression; 
CCR 
[221] 
TFAP2A 
transcription factor AP-2-
alpha 
PB MNC; BM 
MNC 
CP-CML; BP-CML; 
disease progression  
[148] 
TFAP2E 
transcription factor AP-2 
epsilon 
K562; PB MNC disease progression [133] 
TP53 
p53 transcription factor; 
tumor suppressor 
PB MNC ND [127] 
TRCP4 
transient receptor 
potential cation channel 
PB MNC; BM 
MNC 
CP-CML; BP-CML [148] 
            
CD7 T-cell leukemia antigen 
hypomethylation 
BM lin-CD34+ CP-CML [222] 
DDX43 
ATP-dependent RNA 
helicase 
BM MNC all CML stages [223] 
LHX2 LIM-domain protein BM MNC ND [224] 
LINE1, Alu, 
Satellite-alpha 
and Satellite-2 
repetitive DNA elements BM MNC disease progression [225] 
SOCS1 
repressor of cytokine 
signalling 
PB MNC; BM 
MNC 
ND [226] 
 
Table 4 
Table 4. Non-coding RNAs (ncRNAs) dysregulated in CML. Column one: ncRNA name. Column two: class of ncRNA. Column 
three: putative target gene or competitor RNA (predicted or experimentally validated). Column four:  Column four: CML cell type 
studied (primary patient material or cell lines). Column five: clinical significance as described in the cited reference(s). Column six: 
cited reference(s). Abbreviations: PB = peripheral blood; BM = bone marrow; MNC = mononuclear cells; LSC = leukemic stem cell; 
CP = chronic phase; BP = blast phase; IFN = interferon; WBC = white blood count; CCR = complete cytogenetic remission; MMR = 
major molecular response; ND = not determined.  
 
ncRNA CLASS 
PUTATIVE 
TARGET/COMPETITOR 
CML CELL TYPE CLINICAL SIGNIFICANCE REFERENCE 
lncRNA-BGL3 
ceRNA 
PTEN K562, PB MNC ND [227] 
ceRNA network 
DLGAP1, DST, PHLDB2, 
SAMD9, STON1, TRIM6, 
MAGEA12  
K562 disease progression [228] 
            
miR-126 
exosomal 
miRNA 
CXCL12, VCAM1 LAMA84 ND [120] 
miR-1908 ND K562 ND [229] 
miR-210 EFNA3 K562 ND [230] 
miR-298 ND K562 ND [229] 
miR-92a ND K562 ND [231] 
            
ncCHES1 
lncRNA 
CHES1 PB MNC dasatinib resistance [232] 
ncPRKCB1 PRKCB1 PB MNC dasatinib resistance [232] 
ncRNPEP RNPEP PB MNC dasatinib resistance [232] 
            
let-7a,b,d,f,g,i 
miRNA 
BCL2L1 K562 ND [151] 
miR-100 ND BM MNC 
CP-CML; imatinib 
resistance 
[166] 
miR-101 JAK2 PB MNC; K562 
CP-CML; imatinib 
sensitivity 
[150, 233] 
miR-103 CDK6; PIK3R1 PB MNC ND [152] 
miR-106a ND 
PB MNC; PB 
CD34+; K562 
CP-CML; BP-CML [149, 152] 
miR-106b TGFBR2, CCND1 PB MNC CP-CML [150] 
miR-107 CRKL K562 ND [151] 
miR-10a 
USF2 among many 
others 
BM MNC; BM 
CD34+ 
CP-CML [162] 
miR-10b CDKN2A K562 ND [151] 
miR-125a-5p AKT3 K562 ND [151] 
miR-125b AKT3, CDKN2A K562 ND [151] 
miR-126 
MAPK8, CRK, KRAS, 
TGFBR2, CCND1, 
RUNX1, TP53 
PB MNC; BM MNC 
CP-CML; BP-CML; imatinib 
resistance 
 [150, 152, 166] 
miR-128 CRKL K562 ND [151] 
miR130a CCN3 
K562; BM stroma; 
PB MNC 
CML diagnosis [165, 234] 
miR-130b TGFBR2, CCN3 K562 ND [151, 234] 
miR-134 ND BM MNC 
CP-CML; imatinib 
resistance 
[166] 
miR-141 ND BM MNC 
CP-CML; imatinib 
resistance 
[166] 
miR-142-3p 
ACVR2A, ANK3, 
ARHGEF12, CCNJ, 
MAP3K11, MYH9, 
MYO5A, RBM47, RHEB, 
RNF38, ZNF618, 
C18orf25 
PB MNC CP-CML; prognostic [163] 
miR-144 
TGFBR2; SMAD4; 
RUNX1 
PB MNC; K562-R 
(R= imatinib 
resistant) 
imatinib resistance [152, 235] 
miR-145 TGFBR2 K562 ND [151] 
miR-146a 
MAPK8, SMAD4, TP53, 
C12orf36, MMP16, 
NFASC; NFKB1 
PB MNC; BM 
trephines; K562 
CP-CML; imatinib response [150, 151, 163, 164] 
miR-148b ND PB MNC imatinib discontinuation  [236] 
miR-150 
E2F3, BCR, CBL, 
CCND1, TP53, MYB, 
C12orf36, MMP16, 
NFASC 
PB MNC; BM MNC; 
BM CD34+; BM 
trephines; BM 
stroma 
CP-CML; BP-CML; 
relapse; imatinib response 
[150, 152, 162-165] 
miR-151 ND 
BM MNC; BM 
CD34+ 
CP-CML [162] 
miR-152 ND PB MNC CP-CML [150] 
miR-155 
E2F2, E2F3, BCR, CBL, 
KRAS, SOS1, TGFBR2, 
SMAD4, CCND1, 
PIK3R1, RUNX1, TP53, 
JARID2, BACH1 
PB MNC; K562; 
Meg-01; BM 
trephines 
CP-CML; imatinib response [150, 152, 164, 237] 
miR-15a CRKL PB MNC; K562 CP-CML [150, 151] 
miR-16-1 
E2F3, BCR, KRAS, 
CCND1, TP53 
PB MNC CP-CML [150] 
miR-17 
E2F2, E2F3, CRK, 
MAPK1, ACVR1B, 
CCND1, RUNX1 
PB MNC BP-CML [150, 152] 
miR-17-3p ND K562;  PB CD34+ CP-CML [149, 152] 
miR-17-5p ND K562; PB CD34+ CP-CML [149] 
miR181 family MCL1 
MYL-R; K562-R (R 
= imatinib resistant) 
TKI resistance [238] 
miR181a RALA, SOS1, PIK3R3 
PB MNC; CD34+; 
K562 
imatinib sensitivity  [152, 239, 240] 
miR-181c 
PBX3, HSP90B1,NMT2, 
RAD21 
BM MNC 
CP-CML; imatinib 
resistance 
[241] 
miR-183 ABCA1 BM MNC 
CP-CML; imatinib 
resistance 
[166] 
miR-188-5p CRKL K562 ND [151] 
miR-18a ARHGAP26 
K562, PB MNC, PB 
CD34+ 
CP-CML [149, 192] 
miR-18b ARHGAP26 PB MNC CP-CML [192] 
miR-19 CCND1 PB MNC BP-CML [152] 
miR-191 ND BM MNC 
CP-CML; imatinib 
resistance 
[166] 
miR-193a-3p CRKL K562 ND [151] 
miR-195 AKT3; IKBKB K562 ND [151] 
miR-196b BCR-ABL1, HOXA9 K562; BM MNC 
CP-CML; imatinib 
resistance 
[166, 242] 
miR-199a ABCC5 BM MNC 
CP-CML; imatinib 
resistance 
[166] 
miR-199a-5p IKBKB K562 ND [151] 
miR-199b ND 
PB MNC; BM MNC; 
K562; CMLT1 
CML with der(9) deletions; 
imatinib resistance 
[243-245] 
miR-199b-5p 
ACVR2A, ANK3, 
ARHGEF12, CCNJ, 
MAP3K11, MYH9, 
MYO5A, RBM47, RHEB, 
RNF38, ZNF618 
PB MNC; BM 
trephines 
CP-CML; imatinib response [163, 164] 
miR-19a 
RAF1; KRAS; MAPK1; 
TGFBR2; PIK3R3 
PB MNC; K562; PB 
CD34+ 
CP-CML; BP-CML [149, 151, 152] 
miR-19b ND PB MNC; PB CD34+ CP-CML; BP-CML [149, 152] 
miR-203 ABL1; BCR-ABL1 
K562; PB MNC; BM 
MNC 
imatinib 
response/sensitivity 
[246-248]  
miR-20a 
E2F3, BCR, KRAS, 
TGFBR2, CCND1, 
RUNX1, TP53, AKT3 
PB MNC; K562; PB 
CD34+ 
CP-CML; BP-CML [149-152] 
miR-21 
E2F1, E2F3, BCR, 
KRAS, TGFBR2, 
SMAD3, SMAD4, 
CCND1, RUNX1, TP53, 
PDCD4, BCL2 
PB MNC; BM MNC; 
K562 
CP-CML; BP-CML; 
sensitivity to arsenic 
trioxide 
[150, 151, 249-251] 
miR-212 ABCG2 PB CD34+; K562 
CP-CML; BP-CML; imatinib 
response 
[149, 252] 
miR-214 IKBKB K562 ND [151] 
miR-215 
WNK1, ALCAM, RB1, 
ZEB2, PTPRT, others 
plasma imatinib discontinuation  [253] 
miR-217 DNMT3A K562 TKI resistance [254] 
miR-218 IKBKB K562 ND [151] 
miR-219-2 ND 
PB MNC; BM MNC; 
K562; CMLT1 
CML with der(9) deletions [243-245] 
miR-219-5p XIAP K562 ND [62] 
miR-22 AKT3 K562 ND [151] 
miR-221 CRKL, PI3KR1 PB MNC BP-CML [152] 
miR-222 E2F2, CBL, CDKN1B PN MNC BP-CML [152] 
miR-224 ND BM MNC 
CP-CML; imatinib 
resistance 
[166] 
miR-23a ND 
BM trephines; BM 
stroma; PB MNC; 
BM MNC 
CP-CML; imatinib 
response/resistance; CML 
diagnosis 
[164-166, 255] 
miR-25 HDM2 K562 ND [151] 
miR-26a ND BM MNC 
CP-CML; imatinib 
resistance 
[166] 
miR-29 family RNAse-L K562 ND  [256] 
miR-29a 
SMAD3, CCND1, TP53,  
TGFBR2, TGFB2 
PB MNC; BM MNC; 
K562 
CP-CML; imatinib 
resistance 
[150, 151, 166] 
miR-29b 
ABL1, BCR-ABL1, 
TGFB2 
BM MNC; K562 CP-CML [151, 167] 
miR-29c TGFB2; ABCB6 BM MNC; K562 
ND; CP-CML; imatinib 
resistance 
[151, 166] 
miR-301a,b TGFBR2 K562 ND [151] 
miR-30a 
ATG5, BECLIN1, BCR-
ABL1, ABL1 
K562; BM MNC 
imatinib 
response/sensitivity  
[257, 258] 
miR-30b ND BM MNC 
CP-CML; imatinib 
resistance 
[166] 
miR-30c ND BM MNC 
CP-CML; imatinib 
resistance 
[166] 
miR-30e ABL1, BCR-ABL1 PB MNC; K562 
CP-CML; imatinib 
sensitivity 
[259] 
miR-31 CBL; E2F2 
PB MNC; K562; 
Meg-01 
CP-CML [237] 
miR-32 HDM2 K562 ND [151] 
miR-320a BCR, ABL1 PB MNC CP-CML [260] 
miR-323-3p NFKB1 K562 ND [151] 
miR-326 SMO 
BM MNC; BM 
CD34+ 
CP-CML; imatinib 
resistance; BP-CML 
[166, 261] 
miR-328 PIM1, hnRNP E2 K562 BP-CML [252, 262] 
miR-330-3p IRF8 PB MNC CP-CML [192] 
miR-339-5p HMD2 K562 ND [151] 
miR-34a SRC K562; BM MNC ND [263] 
miR-362-5p GADD45A PB MNC CP-CML; imatinib response [264] 
miR-370 FOXM1; TGFBR2 BM MNC; K562 
disease progression; 
response to omacetaxine 
[151, 265] 
miR-377 IKBKB K562 ND [151] 
miR-409-3p IKBKB K562 ND [151] 
miR-411 TGFBR2 K562 ND [151] 
miR-422b ND 
BM trephines; BM 
MNC 
CP-CML; imatinib 
response/resistance 
[164, 166] 
miR-424 ABL1 
PB MNC; K562; BM 
trephines 
imatinib sensitivity; atypical 
CML (Ph-) 
[266, 267] 
miR-451 BCR-ABL1 
PB MNC; K562-R 
(R= imatinib 
resistant) 
CP-CML; relapse; TKI 
response/failure/resistance; 
MMR 
[150, 152, 168-170, 
235] 
miR-454 TGFBR2 K562 ND [151] 
miR-485-3p CTBP1 K562 ND [151] 
miR-486-5p 
CTBP2, FOXO1, PTEN, 
ARID4b, AFF3, TWF1,  
K562; BM CD34+ ND [151, 268] 
miR-493-5p IL8 K562 imatinib response; CP-CML [269] 
miR-494 IKBKB K562 ND [151] 
miR-520a ND BM MNC 
CP-CML; imatinib 
resistance 
[166] 
miR-520a-5p STAT3 K562 capsaicin sensitivity [270] 
miR-562 IRF8 PB MNC CP-CML [192] 
miR-564  E2F3, AKT2 
PB MNC; K562; 
Meg-01 
CP-CML [237] 
miR-568 ND PB MNC CP-CML [150] 
miR-579 ARHGAP26 PB MNC CP-CML [192] 
miR-607 ND PB MNC CP-CML [150] 
miR-625 NFKB1, CDKN2A K562 ND [151] 
miR-7 ND BM MNC 
CP-CML; imatinib 
resistance 
[166] 
miR-9 ND PB MNC 
CP-CML; 
pterocarpanquinone-LQB-
118 sensitivity  
[150, 271]  
miR-92 ND K562; PB CD34+ CP-CML [149] 
miR-92a-1 
E2F3, BCR, KRAS, 
SMAD4, CCND1, 
RUNX1, TP53 
PB MNC CP-CML [150] 
miR-96 ND 
BM MNC; BM 
CD34+ 
CP-CML [162] 
miRNA network numerous in silico only ND [272] 
 
 
